Stay updated with breaking news from Poster Presentation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
AT-01 shows increased LV uptake and LV amyloid activity in all cardiac ATTR and AL subjects, but in none of the controls (100% accuracy) AT-01 demonstrates
AT-01 shows increased LV uptake and LV amyloid activity in all cardiac ATTR and AL subjects, but in none of the controls (100% accuracy)AT-01 demonstrates...
Tenalisib (RP6530, selective dual PI3K d/? inhibitor with additional SIK3 inhibitory activity) showed encouraging results with a clinical benefit rate (CBR) of 57.5% from an ongoing phase II trial
Late-breaking data from DESTINY-Lung02 phase 2 trial of ENHERTU in patients with previously treated HER2 mutant metastatic non-small cell lung cancer to be featured Proffered paper presentation
Nobelpharma Will Also Have an Exhibit at the ConferenceBETHESDA, Md., Aug. 9, 2022 /PRNewswire/ -- Nobelpharma America, LLC, a pharmaceutical and ...